CXCR4 and leukemia: Targeting CXCR4 effectively mobilizes AML cells to the peripheral blood, prevents extramedullary organ infiltration and metastasis, and exhibits significant anti-leukemia efficacy with minimal toxic side effects, suggesting its potential as a personalized therapeutic target for AML [97,98].